These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12563704)

  • 21. [Reiter's syndrome and human immunodeficiency virus infection].
    de Mello e Silva AC; Boulos M
    Rev Hosp Clin Fac Med Sao Paulo; 1998; 53(4):202-4. PubMed ID: 9922502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline.
    Neumann S; Kreth F; Schubert S; Mossner J; Caca K
    Clin Infect Dis; 2003 Jun; 36(12):1628-9. PubMed ID: 12802773
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of infliximab in resistant psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I; Macchioni P; Padula A; Niccoli L; Catanoso MG; Scocco GL; Boiardi L
    Arthritis Rheum; 2003 Aug; 49(4):541-5. PubMed ID: 12910561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients.
    Ting PT; Koo JY
    Int J Dermatol; 2006 Jun; 45(6):689-92. PubMed ID: 16796629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein.
    Cauza E; Hanusch-Enserer U; Frischmuth K; Fabian B; Dunky A; Kostner K
    J Clin Pharm Ther; 2006 Apr; 31(2):149-52. PubMed ID: 16635048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection.
    Arnett FC; Reveille JD; Duvic M
    Rheum Dis Clin North Am; 1991 Feb; 17(1):59-78. PubMed ID: 2041889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV infection is not associated with Reiter's syndrome: data from the Johns Hopkins Multicenter AIDS Cohort Study.
    Hochberg MC; Fox R; Nelson KE; Saah A
    AIDS; 1990 Nov; 4(11):1149-51. PubMed ID: 2282189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy].
    Altinbaş A; Ozkaya G; Büyükaşik Y; Unal S
    Mikrobiyol Bul; 2007 Jul; 41(3):473-6. PubMed ID: 17933262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
    Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
    J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.